Lee’s Story
Lee’s story On 9th April 2025, I discovered I was pregnant. As a first-time mum, I was overjoyed.…
Trials Acceleration Programme
Help Fund A NurseThe TAP network is a national infrastructure that links the UK’s leading blood cancer centres through a team of specialist research nurses funded by Cure Leukaemia. This unique setup ensures that adults with blood cancers such as leukaemia, lymphoma and myeloma can be offered access to clinical trials of pioneering new treatments wherever they live in the UK.
The TAP network is made up of 15 blood cancer centres covering a catchment area of 30 million people, costing £1million to run each year.
By removing delays in opening and running trials, TAP has already enabled more than 1,200 patients to join 22 ground-breaking studies. It has cut the average trial set-up time from around 30 months to less than a year and secured over £100 million worth of free drugs for the NHS, meaning patients benefit sooner while the health service saves vital resources.
TAP has made the UK one of the most attractive places in the world for pharmaceutical companies to run clinical trials, accelerating progress towards new standard treatments for blood cancer patients.
Clinical Trials delivered through the TAP Network
Over 1,200 patients have benefited from clinical trials as part of the TAP Network
PRIZM+
This pioneering Phase 2 platform trial is evaluating Zanubrutinib therapy in adults with relapsed brain lymphoma. In the first year, 20 patients with this rare and aggressive blood cancer were recruited, with first results due to be presented at an international conference next month. Later this year, recruitment will re-commence for a further 20 patients using a world-first three-drug combination, offering long-term hope for those facing limited treatment options.
STELLAR
A Phase 2 randomised trial for adults with Richter’s syndrome, a rare and aggressive form of lymphoma. The STELLAR trial is the first randomised trial for Richter’s syndrome in the UK, and it demonstrates the nation’s growing ability to run trials in rare diseases. The study also includes crucial translational research that will help tailor future therapies.
AMMO
One of the TAP Network’s highest recruiting studies, AMMO trial tests a new drug in treating and extending the lives of patients with a rare bone marrow cancer, where treatment options are very limited. The treatment can be taken orally at home, making it much more convenient for patients.
AMMO Trial Phase 2 Clinical Trial presented at ASH Conference
FEDORA
Focused on patients with Myelofibrosis, the Fedora trial is tackling a critical area of unmet need, gathering information about whether a combination of treatments is tolerated, and whether it provides a therapeutic benefit to patients. The FEDORA Trial has now completed recruitment, with results expected to be published soon.
Read Jonathan's Story
How Cure Leukaemia Research Nurses Make An Impact
Inspiring Patient Stories
Abigail’s Story
One of our top Paris Marathon fundraisers has already raised over £4,000, with still three months to go…
Christine’s Story
My name is Christine, and I want to share my experience of living with Myeloma in the hope…
Steve’s Story
Is there a particular reason you’ve chosen to support Cure Leukaemia? “By 2014, after two years of wonderful…
Morgan’s Story
Morgan was diagnosed in 2019 with Acute Lymphoblastic Leukaemia (ALL) and is currently undergoing treatment for ALL at…
Kathryn’s Story
Q: How were you first diagnosed, and what was that experience like? Kathryn: “My diagnosis came completely out…
Elizabeth’s Story
At 87 years old, Elizabeth Brown is living proof that age should never be a barrier to treatment…
Neil’s Story
Neil Morris, a 44-year-old HR director from Abingdon, Oxfordshire, had always been fit and active, completing marathons and…
Rob’s Story
In 2006, aged 37 years old. Rob noticed a lump on the back of his head and swollen…
Help Fund a Cure Leukaemia Research Nurse
Without Cure Leukaemia Research Nurses, clinical trials do not happen. By making a donation, you're helping give hope to blood cancer patients across the globe